Education
About Us
Working with TipRanks
Follow Us
Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
Total Valuation
Balaxi Pharmaceuticals Limited has a market cap or net worth of ₹555.06M. The enterprise value is ₹5.29B.
Market Cap₹555.06M
Enterprise Value₹5.29B
Share Statistics
Balaxi Pharmaceuticals Limited has 11,041,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,041,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Balaxi Pharmaceuticals Limited’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 82.52%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)82.52%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.93
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Balaxi Pharmaceuticals Limited is 0.00. Balaxi Pharmaceuticals Limited’s PEG ratio is 0.31.
PE Ratio0.00
PS Ratio0.00
PB Ratio3.27
Price to Fair Value0.00
Price to FCF54.46
Price to Operating Cash Flow10.85
PEG Ratio0.31
Income Statement
In the last 12 months, Balaxi Pharmaceuticals Limited had revenue of 2.89B and earned 250.70M in profits. Earnings per share was 4.54.
Revenue2.89B
Gross Profit1.18B
Operating Income286.70M
Pretax Income286.70M
Net Income250.70M
EBITDA305.64M
Earnings Per Share (EPS)4.54
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Balaxi Pharmaceuticals Limited pays an annual dividend of ₹0.5, resulting in a dividend yield of ―
Dividend Per Share₹0.5
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change-58.62%
50-Day Moving Average55.09
200-Day Moving Average74.29
Relative Strength Index (RSI)38.12
Average Volume (3m)381.66K
Important Dates
Balaxi Pharmaceuticals Limited upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 30, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend DateJul 01, 2022
Financial Position
Balaxi Pharmaceuticals Limited as a current ratio of 0.00, with Debt / Equity ratio of 3.21%
Current Ratio0.00
Quick Ratio0.00
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Balaxi Pharmaceuticals Limited has paid 35.99M in taxes.
Income Tax35.99M
Effective Tax Rate0.13
Enterprise Valuation
Balaxi Pharmaceuticals Limited EV to EBITDA ratio is 0.46, with an EV/FCF ratio of -0.24.
EV to Sales0.05
EV to EBITDA0.46
EV to Free Cash Flow-0.24
EV to Operating Cash Flow-0.37
Balance Sheet
Balaxi Pharmaceuticals Limited has ₹608.67M in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹608.67M billion.
Cash & Marketable Securities₹608.67M
Total Debt₹0.00
Net Cash-₹608.67M
Net Cash Per Share-₹55.13
Tangible Book Value Per Share₹0.00
Margins
Gross margin is 29.99%, with operating margin of 9.93%, and net profit margin of 8.68%.
Gross Margin29.99%
Operating Margin9.93%
Pretax Margin9.93%
Net Profit Margin8.68%
EBITDA Margin10.58%
EBIT Margin9.93%
Analyst Forecast
The average price target for Balaxi Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―